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By-products of Heparin production 
provide a Diverse source of 
Heparin-like and Heparan sulfate 
Glycosaminoglycans
sarah L. taylor  1, John Hogwood2, Wei Guo3,4, edwin A. Yates1 & Jeremy e. turnbull1
Global production of pharmaceutical heparin (Hp) is increasing, and the production process from 
raw mucosal material results in large amounts of waste by-products. these contain lower sulfated 
Hp-like and heparan sulfate (Hs), as well as other glycosaminoglycans, which are bioactive entities 
with pharmaceutical potential. Here we describe the first purification, structural and functional 
characterisation of Hp-like and Hs polysaccharides from the four major by-product fractions of 
standard heparin production. Analysis of the by-products by disaccharide composition analysis and 
NMR demonstrated a range of structural characteristics which differentiate them from Hp (particularly 
reduced sulfation and sulfated disaccharide content), and that they are each distinct. Functional 
properties of the purified by-products varied, each displaying distinct anticoagulant profiles in different 
assays, and all exhibiting significantly lower global and specific inhibition of the coagulation pathway 
than Hp. The by-products retained the ability to promote cell proliferation via fibroblast growth factor 
receptor signalling, with only minor differences between them. These collective analyses indicate 
that they represent an untapped and economical source of structurally-diverse Hp-like and Hs 
polysaccharides with the potential for enhancing future structure-activity studies and uncovering new 
biomedical applications of these important natural products.
Most of the globally important pharmaceutical, heparin (Hp), is extracted currently from porcine intestinal 
mucosa, although some is still obtained from bovine sources, mainly in South America. Extraction of the crude 
intestinal material yields approximately 0.8 Kg per animal which, following an extensive purification proce-
dure provides typically 180–260 mg of Hp from each animal1,2. With the large number of animals (~1 billion 
per annum) required to meet the global demand for Hp, currently ~100 metric tonnes per annum3, many more 
tonnes of waste products are produced. Since the expanding global market for Hp is set to surpass 10 billion 
dollars by 2020, the increase in demand for raw porcine mucosal material for the isolation of the pharmaceutical 
product will also elicit an increase in the resulting by-products.
Owing to the specific size range of pharmaceutical Hp (average molecular weight typically ~12–15 kDa) and 
the sulfation selection criteria that are applied during the extraction and purification processes, less-sulfated or 
shorter Hp chains, as well as other GAGs including HS and chondroitin sulfate/dermatan sulfate (CS/DS), are 
discarded in the by-products. Previous work has demonstrated that HS can be obtained from crude Hp prepa-
rations4, and GAG preparations containing mixtures of Hp-like, HS and CD/DS polysaccharides such as sulo-
dexide5 and danaparoid6 have also been prepared from mammalian mucosa for pharmaceutical use. Thus, Hp 
by-products could provide a wider potential source of novel Hp/HS GAGs containing a wealth of structural diver-
sity and biological activities, at the same time making more efficient use of existing material without requiring the 
sacrifice of additional animals. Such materials could be utilised for research, or biotechnological and potentially 
medical purposes, where current supplies are scare and/or expensive.
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The term HS was used originally to describe ‘heparin-like’ compounds that were extracted during the Hp 
manufacturing process7,8. Some authors suggested that Hp and HS were sufficiently similar to each other to enable 
them to be considered versions of the same molecule9, but other studies of HS from cell surface material suggested 
that they may be distinct10. Recent work, mainly concerning GAGs derived from marine organisms, however, has 
re-kindled this debate, since some of these marine-derived materials exhibit compositions that fall between pro-
totypical Hp and HS, and also possess unexpected biological activities11,12. The possibility remains, therefore, that 
the original assertion may be correct and that the distinction between mammalian Hp and HS merely reflects a 
continuum of variations, with specific differences between the source tissues and species studied9.
Hp is a polydisperse linear polysaccharide whose detailed sequence is complex and variable between animals. 
In broad terms, Hp is composed of repeating 1–4 linked disaccharides comprising α L-iduronate/β D-glucuronate 
(IdoA/GlcA) and α D-glucosamine (GlcN). The highly anionic nature of Hp arises from the presence of carboxyl 
groups and extensive O- and N-sulfation; principally at positions 2 of iduronate and 6 and 2(N) of glucosamine 
but, much less frequently, also at position 3 of glucosamine. This provides Hp with an overall sulfation level of 
1.4–2.5 sulfates per disaccharide unit, but most typically at the higher end of this range9. HS has underlying 
structural similarities to Hp, being composed of the same linkage types and basic monosaccharide units, but in 
different proportions and usually comprises much longer chains. HS possesses higher ratios of GlcA/IdoA and 
GlcNAc/GlcNS compared to Hp, and lower overall sulfation (typically 0.55–1.25 sulfates per disaccharide7 as well 
as better-defined domains of low sulfation (predominantly D-GlcA-D-GlcNAc) interspersed with shorter, more 
sulfated stretches13,14. It also differs in terms of the cells which produce it; almost all mammalian cells express HS, 
in contrast to Hp, which is produced by mast cells.
Hp is used widely as an anticoagulant in the clinic owing to its interaction with a number of serpins of the 
blood clotting cascade. Most notably, Hp potentiates the activity of antithrombin (ATIII) for subsequent inhi-
bition of Factor Xa and IIa (thrombin). However, the nature of the interactions in the two cases are quite dis-
tinct. In the case of Factor Xa, a strong interaction between Hp and ATIII involves a pentasaccharide sequence, 
the most active form of which includes a central tri-sulfated glucosamine residue flanked by GlcA and IdoA2S. 
Interestingly, whilst a central 3-O-sulfated glucosamine (N-, 3-O- and 6-O-trisulfated glucosamine) is a key com-
ponent in this known pentasaccharide sequence that binds strongly to antithrombin, the 3-O-sulfate modification 
to glucosamine also occurs in sequences which do not bind antithrombin with high affinity, and has been identi-
fied in HS from a variety of diverse sources with varying abundance15–19. Functionally, Hp can increase the affinity 
of ATIII for Factor Xa by ~1000-fold20. In contrast, the dual interaction between ATIII and Factor IIa requires a 
much longer heparin stretch, of at least 15 residues, but the sequence requirements are somewhat more relaxed; 
higher sulfation levels generally provide increased activity20,21. These differences led to the development of low 
molecular weight heparin (LMWH) with the ability to interact mainly with ATIII and culminated in development 
of the pentasaccharide drug Arixtra. Other direct interactions do occur between Hp and proteins of the blood 
clotting cascade, however, including Factors IX, XI and XII. While Hp has been optimised to some extent to pro-
vide a degree of selectivity in its interactions in the blood clotting cascade, it has also been identified as binding 
to hundreds of other proteins22. It is presumed that these interactions arise from the structural similarity between 
Hp and the ubiquitously expressed HS but, in most cases, interactions with HS have not been studied explicitly. 
In a recent sequence-based survey of 439 Hp binding proteins, no consensus sequence on the surfaces of these 
proteins for Hp binding emerged23 and, furthermore, the extent of true sequence specificity evident in this system 
has been questioned, leading to the suggestion that, ultimately, this class of compounds may provide a means of 
modulating protein networks more effectively than individual proteins24–26. In any case, it is evident that there 
are a considerable number of potential interactions that Hp and similar compounds could make, positioning 
HS-protein interactions as a crucial regulatory axis in biological processes. Importantly, this ultimately may be 
exploited for diverse pharmaceutical purposes. However, the further detailed study of these interactions requires 
access to diverse sources of HS structures.
The aim of the present work was to undertake the first systematic analysis of the structural and functional 
properties of Hp/HS GAGs in by-products that are discarded during the Hp manufacturing process. We charac-
terised the four major by-product fractions in terms of their structural properties (such as disaccharide compo-
sition, sulfation and chain length), as well as biological properties (such as anticoagulant activity and activation 
of fibroblast growth factor signalling). The findings support the view that Hp by-products provide a rich resource 
of Hp-like/HS GAGs for structure-activity studies and have the potential to be exploited in future biomedical 
applications.
Materials and Methods
Purification and Recovery of Hp/HS By-Products. 20 g of each crude by-product sample (Fig. 1; sup-
plied by Chenzhong Biopharma, Shandong, China) was dissolved in 100 ml of chondroitinase buffer (100 mM 
tris acetate (Sigma, UK) pH 8.0). Samples were incubated until they had dissolved completely and had lost their 
viscosity. For chondroitinase digestion samples were incubated with 500 mU of chondroitin ABC-ase (Sigma-
Aldrich, UK) overnight at 37 °C (all subsequent incubations are at 37 °C). After 24 hours, 20 ml of DNase buffer 
(10 mM tris acetate (pH 8.0), 25 mM magnesium chloride (Sigma, UK), 0.5 mM calcium chloride (Sigma, UK)) 
was added to the sample and in the presence of 500mU DNase and incubated for a further 4 hours. Further 
overnight digestions were conducted with 250 mU RNase in 20 ml of standard RNase buffer (10 mM tris acetate 
pH 8.0, 5 mM EDTA, 8 mM sodium acetate (Sigma, UK)) and subsequently 280 U of Pronase in 20 ml of buffer 
followed (10 mM tris acetate, 10 mM calcium acetate pH 7.0 (Sigma, UK)).
By-products were separated from the subsequent products of enzymatic digestion by weak anion exchange 
chromatography on diethylaminoethanol (DEAE) beads (batch preparation in 50 ml Falcon tubes – GE 
Healthcare, UK). 100 ml of 0.01 M phosphate buffered saline (PBS- Sigma, UK) and 100 ml of 0.3 M NaCl 
(ThermoFisher Scientific, UK) were used to clean the beads of all unbound non-HS products, HS was eluted 
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with 2.0 M NaCl (100 ml). To remove the salt, the sample was dialyzed with 3.5 kDa cut off tubing (ThermoFisher 
Scientific, UK) over a 24-hour period with two 5 L changes of ddH2O.
Separation of Purified Intact By-Products by Anion Exchange Chromatography. For analytical 
purposes, 200 µg of intact, clean crude heparin by-product was separated on a 1 ml Hitrap Q HP column (GE 
Healthcare, UK) over a 45 min programme set with two column volume washes of 0.5 M NaCl followed by a step 
gradient of 0.5, 1.0, 1.2, 1.4, 1.6, 2 M NaCl (10 ml of each) following a protocol similar to Griffin et al.4. Peaks were 
detected by following absorbance at 232 nm with the expectation that peaks would be visible across the range of 
NaCl concentrations and that more highly sulfated structures would be expected to elute at higher concentrations.
Carbon-13 nuclear magnetic resonance spectroscopy. Each sample (20 mg) was dissolved in deu-
terated water (0.7 ml, >95% D, Sigma-Aldrich, UK), particulate matter was removed by benchtop centrifugation 
(5 mins) and the sample then transferred to a 5 mm NMR tube. One dimensional 13C spectra were recorded at 
Figure 1. Flowchart depicting the major steps in the production of pharmaceutical Hp and the points at which 
the major four by-product fractions designated here as A-D were obtained. The production from porcine 
intestine at a slaughterhouse to final pharmaceutical Hp and LMWH, involves a clean-up process with multiple 
steps to ensure that all contaminants are removed, providing final products of pharmaceutical grade for human 
use. Estimates of typical yield quantities (kilograms) of the various intermediates, by-products and products 
from a production process starting with ~1800 intestines are as shown.
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313 K on a Bruker 600 MHz spectrometer (Bruker, Germany) with 100 uM DSS (4,4-dimethyl-4-silapentane-1-su
lfonic acid) as the external reference (0 ppm). Data sets for all spectra were processed in Mestrenova (Mestrelab, 
Spain). Signals were assigned according to the literature27,28.
Compositional Analysis of By-Products by Digestion with Heparinase I, II and III and 
SAX-HPLC. Following clean-up, by-products were solubilised in heparinase buffer to make a solution of 
10 mg/ml. 200 µg of by-products were digested with 2.5 mU of heparinase III, I and II (IBEX, Montreal, Canada) 
added sequentially at 2 hour intervals, with heparinase II left incubating at 37 °C overnight. Further digestion 
with fresh aliquots of all three heparinases was performed for 2 hours, to ensure samples were digested fully; no 
evidence of significant polymetric material was found by gel electrophoresis (data not shown). The products of 
digestion were separated according to charge on a strong anion exchange Propac PA1 column (4 mm diameter 
×250 mm length- Dionex, UK), eluted with a linear gradient of 0–2 M NaCl, over 60 mins at 1 ml/min. Product 
peaks were detected by UV at 232 nm and samples were compared to 8 disaccharide standards of known structure 
(Dextra Labs, UK) also separated on the same column and under the same conditions.
Molecular Weight Determination. Determination of weight average molecular weights for all samples 
was carried out using size exclusion chromatography on an Agilent GPC-50 (Agilent, Stockport, UK). The USP 
Heparin Sodium Molecular Weight Calibrant RS (US Pharmacopeial Convention, USA) was used to calibrate the 
system as previously described29.
Antithrombin Dependent APTT, anti Xa and HCII anti-IIa/IIa assays. The test samples were assayed 
against the 6th International Standard for Unfractionated Heparin (07/328, NIBSC, UK) using an automated 
coagulometer (ACL-TOP 550, Werfen Ltd, Warrington, UK). Dose response curves, consisting of at least three 
dilutions in replicate were assayed for each test material and the standard. Analysis of data was carried out in 
accordance with European Guidelines30 for biological materials using CombiStats 5.0 (European Directorate 
of the Quality of Medicine, France). Specific activities for each method were estimated using parallel line bio-
assay model in CombiStats. Plasma APTT, antithrombin dependent anti-IIa and anti-Xa and heparin cofactor II 
dependent anti-IIa assays were carried out as previously described31.
BaF3 cell proliferation Assay. BaF3 (B-lymphoid) cells transfected with an FGFR1c receptor (gifted 
by Dave Ornitz, Washington State University, USA) were grown to confluence in a T75 flask (ThermoFisher 
Scientific, UK) in normal growth media (500 ml RPMI (Gibco, UK), 10% FBS (ThermoFisher, UK) and 50 µg/
ml streptomycin (ThermoFisher Scientific, UK) supplemented with 2 ng/ml IL-3 (R&D systems, UK)). Cells 
were washed twice with normal growth medium (minus IL-3) by centrifugation and aspiration before being 
re-suspended in an appropriate amount of normal growth medium (1 × 104/50 µl per well) and plated in tripli-
cate in a 96-well plate (CoStar, UK). As controls for the experiment each of the following were added to the plate 
in 50 µl triplicates: 0.1 nM FGF2 (R&D Systems, UK) + assay media; 1 ng/ml IL-3 + assay media; 100 µg/ml Hp 
(Celsus, US) or by-products + assay media; and assay media alone. 50 µl of assay media containing 0.1 nM FGF2 
was added to the plate in triplicate with the following concentrations of Hp or by-products: 1, 3, 10, 30 100 µg/ml.
Cells were incubated in test conditions at 37 °C in 5% CO2 for 72 hours before adding 5 µl of 5 mg/ml 
3-(4,5-dimethylthiazol-2-YI)-2,5-diphenyltetrazolium bromide (MTT, Sigma, UK) followed by a further 4-hour 
incubation. In order to assess the colour change, which was used as a measure of cell proliferation, formazan is 
solubilised with  50 µl of 10% SDS/0.01 N HCL (Sigma-Aldrich, UK) per well and incubated overnight. Plates 
were read on a MultiScan Ex plate reader (ThermoFisher, UK) at 570 nm.
Results
Anion exchange chromatography demonstrates distinct sulfation profiles of the by-prod-
ucts. We obtained a number of by-product fractions for our studies, and focused on the major side product 
fractions labelled A-D in Fig. 1. (in order of their stage of removal in the Hp production process). To initially 
characterise their anionic charge properties, we carried out a comparison by anion exchange chromatography 
(AEC) on a Hitrap Q HP column. Fraction A exhibited low levels of overall sulfation (Fig. 2). The majority of 
Fraction A was displaced from the AEC column prior at 1.0–1.2 M NaCl, although a small amount of residual 
material eluted at 2 M NaCl. Overall, this indicated that Fraction A may be predominantly low/moderately sul-
fated, but still contained some higher sulfated material. For Fractions B and C we observed a major peak at 1.4 M 
NaCl, with additional minor peaks eluted throughout the salt gradient at both lower and higher salt concentra-
tions, including some 2 M material, which is present at higher levels in Fraction C compared to B. These fractions 
were removed at similar stages in the production of Hp, C being produced by a second round of filtration, anion 
exchange and precipitations (Fig. 1). Therefore, it may be relatively unsurprising that their AEC profiles showed 
very similar patterns indicating predominantly moderate sulfation, but also significant heterogeneity. Fraction D, 
which is the last by-product to be removed in the purification process, was distinct in that it contained the highest 
proportion of 2 M-eluting material, but also a significant proportion eluting at only moderate (1–1.2 M) NaCl. 
These results are consistent with Fraction D comprising the highest proportion of highest proportion of highly 
sulfated Hp-like structures. Overall, these results indicated that each by-product was distinct in terms of the 
spread of sulfated species, and that a broad correlation exists between increase overall sulfation of the by-products 
with their later stage of removal in the production process.
Carbon 13 NMR indicates differences in by-products compared to Hp. To further elucidate the 
structure of the by-products carbon-13 nuclear magnetic resonance spectroscopy (13C NMR) is a powerful and 
non-destructive method with which to explore the structure of Hp27,28. Using 13C NMR to compare Hp and each 
of the by-products, it was evident that Hp was substantially more sulfated than the by-product materials (Fig. 3), 
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supporting the SAEC chromatography results (Fig. 2). In addition, Fraction D appeared to the most similar in 
terms of its relatively high level of sulfation, consistent with the AEC data (Fig. 2). However, the ratios of N- and 
O- sulfation of B also showed a comparable level of sulfation to D, with higher levels of N-sulfation (1.3 – B and 
D, Table 1) and both B and D also contained similar amounts of 2-O sulfation (0.7). Fraction B appears to contain 
more 6-O sulfation than D (0.9 vs 0.7). Fraction A contained intermediate sulfation, with the ratios of all 3 sul-
fation patterns being similar to each other (N- 0.8, 2- 0.9, 6- 0.7). Fraction C was the least sulfated sample, with 
Figure 2. Strong anion-exchange chromatography of Hp and by-products. 200 µg of intact samples were 
separated by a step increase in concentration of NaCl (1.0, 1.2, 1.4, 1.6, 1.8 and 2 M, the red line is conductance 
and is an AKTA output with the scale relative to the maximum absorbance peak of the y-axis) at a flow rate of 
0.5 ml/min. Samples were detected by UV at 232 nm.
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all sulfate positions in similar abundance (N- 0.7, 2- 0.8, 6- 0.8). In previous work, N-unsubstituted glucosamine 
residues have been identified in some commercial porcine mucosal HS samples32 but, here, we observed no signif-
icant characteristic signals at 96 ppm for such residues in any of the by-products, or Hp (Fig. 3). Overall the NMR 
data support the view that each by-product is distinct, but also indicated that the rank order of the by-products in 
terms of proportions of sulfations at the key N, 2 and 6 positions was D > B > A > C.
Disaccharide analysis indicates that by-products are structurally distinct from Hp and from each 
other. The samples were compared to Hp at the disaccharide level. Hp is characterised as having low levels of 
the unsulfated disaccharide UA-GlcNAc (<5%) and high levels of the trisulfated disaccharide UA(2S)-GlcNS(6S) 
(typically >60–70% in PMH), giving rise to high average sulfation (~2.5 sulfates per disaccharide). In order to 
compare disaccharide composition of the by-products to Hp, samples were subjected to exhaustive lyase digestion 
and the products of the digestion were separated by strong anion exchange (SAX)-HPLC on a Propac PA1 col-
umn, using a 0–2 M NaCl gradient, with material detected by UV absorbance at 232 nm. Compositional analysis 
at the disaccharide level demonstrated significant differences between each of the by-products, and also to Hp 
as a comparator (Fig. 4a). Fractions B and D contained the highest amount of trisulfated disaccharide (~60 and 
~62% respectively), whereas Hp contained ~68%. Fractions A and C showed statistically significant reduction 
in the proportion of trisulfated ∆UA(2S)-GlcNS(6S) disaccharide which is characteristically the most abundant 
disaccharide in Hp (Table 2). Fractions B and C showed the largest differences at this level when compared to 
Figure 3. One dimensional 13C NMR of Hp and by-products. (A) NMR spectra of 20 mg of samples in D2O 
were recorded at 313 K on a Bruker 600 MHz spectrometer with DSS as the external reference (0 ppm). Signals 
were assigned according to Yates et al.23. Sulfation at glucosamine position 6 is denoted 'A6-6S', at position 2 of 
glucosamine, A2-NS and at position 2 of iduronate, as I2-2S.
Carbon Sample A6 (69 ppm) A2 (57 ppm) I1 (102 ppm)
Sulfated/unsulfated
Hp 3 2.7 2.6
A 0.7 0.8 0.9
B 0.9 1.3 0.7
C 0.7 0.7 0.8
D 0.7 1.3 0.7
Table 1. Ratios of peak height of sulfated/unsulfated residues at A-6, A-2, and I-2 for Hp and by-products. 2-O 
sulfation of iduronic acid is most clearly identifiable by the chemical shift of carbon 1 at 102 ppm. N and 6-O 
sulfation are best identified by changes in signal of carbon 2 and 6 of N-acetylglucosamine at 57 and 69 ppm, 
respectively. 6-O-sulfation in glucosamine (evident in the 13C NMR spectrum at 69 ppm) is referred to as ‘A6’, 
N-sulfation in glucosamine (58 ppm) as ‘A2’ and 2-O-sulfation (monitored by the signal for C-1 in iduronate 
residues (102 ppm) as ‘I1’.
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Figure 4. Disaccharide analysis of Hp and by-products. (a) Following enzymatic digestion with heparinase I, II 
and III samples were separated on a Dionex PA-1 column over a 0–2 M NaCl gradient, products were identified 
by UV at 232 nm. A set of 8 known structures were also run under the same conditions and these were used to 
identify peaks from the samples (Table 2). Percentage peak areas were calculated for each sample, along with 
the SEM and multiple t-tests comparing heparin to the other samples (p = 0.05, n = 3). (b) Analysis of sulfation 
levels and types from disaccharide composition data. From the same data used in 4a, percentage peak areas for 
each sample were grouped into categories to determine other structural compositions. Percentage peak areas for 
no sulfates1, mono- (3, 2, 4) di- (5, 7, 8) and tri- (6) were calculated, with mean and SEM. Multiple comparison 
t-tests (p = 0.05, n = 3) between all sample to Hp were carried out. (c) Percentage peak areas were also grouped 
to examine the positions of sulfation; NS3–6, NA1,2,7,8, 2S [7, 5, 8. 6] and 6S2,4,6,8 were calculated, with mean and 
SEM. Multiple comparison t-test (p = 0.05, n = 3) comparing all samples to Hp.
Peak (in elution order) Structure
1 Δ-UA-GlcNAc
3 Δ-UA-GlcNS
2 Δ-UA-GlcNAc(6S)
7 Δ-UA(2S)-GlcNAc
4 Δ-UA-GlcNS(6S)
5 Δ-UA(2S)-GlcNS
8 Δ-UA(2S)-GlcNAc(6S)
6 Δ-UA(2S)-GlcNS(6S)
Table 2. The structure of 8 standard disaccharides used for HS/Hp comparison. These 8 standards have defined 
structures and elute in a reproducible order.
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Hp. Fraction C exhibited low levels of sulfation overall, with significant decreases in the trisulfated disaccharide 
and concomitant increase in all mono- and di-sulfated structures, except for ∆UA-GlcNS(6S). There was also a 
significant decrease in the unsulfated disaccharide ∆UA-GlcNAc and, similar to fraction C, a significant increase 
in all mono- and disulfated disaccharides, except for ∆UA-GlcNS(6S).
Considerable variation was evident in the proportions of the N-sulfated disaccharides ∆UA-GlcNS and 
∆UA(2S)-GlcNAc(6S) in by-products from different stages of the production process. Fractions A and D 
exhibited the least significant differences from Hp, however, both showed a further difference in content of 
∆UA-GlcNAc(6S) (p = 0.004) and ∆UA(2S)-GlcNS (p = 0.003).
Whilst there are minimal differences between the by-products and Hp in terms of unsulfated disaccharide 
(Fraction B has a significant decrease, p = 0.01 – Fig. 4a and Table 2), there are more notable changes in the levels 
of other disaccharides. All by-products showed a significant increase in monosulfated disaccharides compared 
to Hp, A, p = 0.0005, B, p = 0.001, C, p = 0.0005 and D, p = 0.04. Fraction C also had increased proportions of 
disulfated structures (p = 0.0001) and exhibited a decrease in the trisulfated disaccharide (Table 2).
All by-products showed a lower proportion of disaccharides containing at least one sulfate group, com-
pared to Hp. Structures containing N sulfates are significantly less well-represented in Fractions B (p = 0.0003), 
C (p < 0.0001) and D (p = 0.05). 6-O sulfation is also significantly reduced in Fractions B (p = 0.0003), C 
(p < 0.0001) and D (p = 0.0005), and finally 2-O sulfation in Fraction C was significantly lower than in Hp 
(p = 0.004). This establishes that all by-products are significantly less sulfated than Hp and the production process 
progressively selects for retention of more sulfated species at each purification stage. Overall the data confirmed 
that each by-product sample has a distinct sulfation profile, and that they all differ from Hp.
The by-products differ in average sulfation levels, and fraction C is the least sulfated. Average 
sulfation levels were compared based on the disaccharide composition data from Fig. 4a; as mentioned previously 
Hp is characterised by being highly sulfated containing 2.0 or more sulfates per disaccharide, and consistent with 
this we observed a value of ~2.2 (Fig. 5). Fraction B and D had a similar level of sulfation to Hp, with 2.1 and 2.0 
sulfates per disaccharide, whereas Fraction A was lower at ~1.8. Fraction C was clearly the least sulfated (average 
sulfation of 1.6 per disaccharide unit). This data, based on disaccharide composition, indicates that the rank order 
of the by-products in terms of average sulfation levels was D > B > A > C, consistent with the data obtained by 
NMR (Fig. 3).
the by-products are more polydisperse than Hp. The molecular weight of Hp (~7–20 kDa) is distinct 
to that of HS; the latter containing a greater proportion of longer chains (20–110 kDa)33. Gel permeation chroma-
tography analysis against a broad standard calibrant allowed both weight and number average molecular weights 
(Mw and Mn) to be determined for the fractions, as well as their distributions within defined ranges; Mw 4–16, 
17–28, 29–39 and >40 kDa. The polydispersity, (Mw/Mn), was also calculated from data obtained for Fig. 6. All 
the by-products had higher Mw than Hp, in the range ~17–34 kDa (see Fig. 6), and there is considerable variation 
in both Mw and Mn as the purification progresses. The polydispersity, a measure of the extent of chain length var-
iation in these linear polymers, broadly decreases as the Hp purification process proceeds, and all the by-product 
fractions displayed greater polydispersity than Hp. Any increases in molecular weight may result from selective 
losses from the parental material (disproportionate losses of different molecular weights). Overall this analysis 
of the by-products by gel permeation chromatography suggests that molecular weight criterion is not strongly 
selected during the purification process for Hp.
The by-products have distinct anticoagulant activity profiles and reduced potency compared 
to Hp. As a first step in characterising potential functional differences, we carried out assays of various 
Figure 5. Average number of sulfates per disaccharide in Hp and by-products. Values were calculated from 
each sample triplicate values from Fig. 4a. The SEM was calculated and all samples were compared to Hp via 
multiple t-tests (p = 0.05, n = 3).
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anticoagulant activities of the by-products, in comparison to Hp as a positive control. We measured both the 
activity of the intrinsic and extrinsic anticoagulant cascade. All of the by-products were found to have greatly 
reduced ability to inhibit coagulation compared to Hp. The APTT assay, which measures the intrinsic and com-
mon pathways, including factors II, V, X and fibrinogen, indicated that all by-product fractions were 2.7–9.2 fold 
less able to inhibit coagulation than Hp, with D having the highest and A the lowest activity (Table 3). Specific 
HCII, Anti-Xa and IIa activities were in broad agreement with the global anticoagulant activity of these samples 
reflected in the APTT assay. All fractions were less able than Hp to inhibit these factors, in the same order as in the 
APTT assay (rank order D > B > C > A), with C and A by far the least able to inhibit HCII (A, 16.7 fold, C, 13.6 
fold) FXa (A, 9.2, fold C, 9 fold,) and FIIa (A, 15.6 fold, C, 11.2 fold,) compared to Hp. Thus, all the by-products 
had low anticoagulant activity and were distinct from Hp. But in addition, each also had a distinct profile of rela-
tive activities in the different assays compared to each other.
All the by-products retain the ability to activate FGF2 signalling in a dose-dependent man-
ner. As a further test of the relative bioactivities of the by-products, we also assessed their ability to activate 
cellular signalling by fibroblast growth factor (FGF2). B-lymphoid cells are dependent on the successful activation 
of a transfected FGFR1c or IL-3 receptor. In the absence of either IL-3 or FGF1/2 these cells are unable to induce 
signalling required for their survival and therefore undergo apoptosis. HS and Hp have been shown to be essen-
tial for the successful complex formation by the growth factor and receptor34 and therefore this assay identifies 
those saccharides which are able to induce successful signalling and therefore survival and proliferation of the 
cells. From an initial assessment, all by-product samples stimulated survival and proliferation in a concentration 
dependent manner, similar to that of Hp (Fig. 7). There was minimal impact on cell proliferation at the lowest 
concentration. However, a large increase in proliferation was seen at concentrations between 3 and 30 µg/ml. 
All by-product samples showed significant changes in the induction of proliferation at several concentrations, 
compared to Hp (p < 0.05), particularly at 30 and 100 µg/ml (Fig. 7). Samples B and D showed substantially more 
Figure 6. Molecular weight determination of the by-products by gel permeation chromatography against a 
Hp calibrate. Average molecular weight (Mw) suggested no correlation with purity, however, the polydispersity 
(Pd = Mw/Mn)) was reduced up to and including the removal of Hp. The loss of sample below 100% in the 
detected range was due to the resolution range residing between 4 and above 40 kDa (Hp – 99.7%, A – 94.3%, 
B – 90.3%, C – 94.4%, D – 98.1%). *Mn – number average molecular weight. Average molecular weight (kDa) – 
Hp, 16.6, A, 30.6, B, 18.7, C, 33.5, D, 26.3. Pd – Hp, 1.2, A, 2.2, B, 2.0, C, 2.1, D, 1.7.
Sample Plasma APTT AT anti-IIa AT anti-Xa HCII anti-IIa
Specific Activity – IU/mg (95% CL)
A 22.7(21.9–23.5)
13.4
(12.7–14.1)
23.2
(21.8–24.7)
14.4
(13.2–15.6)
B 70.8(68.4–73.4)
57.4
(54.5–60.5)
60.1
(56.4–64.0)
54.3
(50.0–58.9)
C 22.8(27.8–29.8)
18.6
(17.7–19.6)
23.8
(22.3–25.3)
17.7
(16.2–19.2)
D 77.0(74.4–79.8)
72.9
(66.5–79.9)
79.1
(74.2–84.3)
63.0
(58.1–68.4)
Hp 209(191–229)
209
(196–223)
214
(207–221)
241
(223–261)
Table 3. Anticoagulant activity of the 6th international standard of Hp and Fractions A-D in global APTT and 
specific Xa, IIa and HCII IIa assays.
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activity at higher concentrations compared to Hp along the concentration curve (Fraction B, 100, 30, 3, 0.1 and 
0.03 µg/ml; Fraction D, 100, 30, 10, 0.3 and 0.1 µg/ml – Fig. 7). This suggests that they were better able to activate 
the FGF2/R1c pathway compared to Hp. By-product A, whilst exhibiting a significant increase in proliferation 
over Hp at several concentrations (3 µg/ml and to a lesser extent at 100 and 30 µg/ml), appeared to have, overall, 
comparable activity to Hp. C was the least able to induce proliferation, although higher proliferation levels than 
Hp were observed at 3 concentrations (100, 30 and 0.3 µg/ml).
Discussion
The production of Hp for the pharmaceutical market is extensive, generating ~100 tonnes/annum of active 
Hp pharmaceutical ingredient3. The process for the isolation of what is defined as Hp from porcine mucosa 
selects highly sulfated structures of low polydispersity in chain size, with high anticoagulant potency and reduced 
heterogeneity compared to the GAGs in the raw material. In contrast, we show here for the first time that the four 
major side-fractions, produced as waste materials of this production process, possess lower sulfation and greater 
heterogeneity, increased chain size polydispersity, and lower anticoagulant activity relative to Hp. They are thus 
quite distinct from Hp in terms of both structure and activity, and represent a relatively untapped resource for 
production of Hp-like and HS polysaccharides. Although some mixed GAG preparations such as sulodexide, a 
mixture of LMWH and dermatan sulfate;5 and danaparoid, a mixture of HS, DS and CS35; have been prepared 
from crude mammalian mucosa extracts for pharmaceutical use5,6 details of their structural characterisation have 
been largely lacking until recently36. HS GAGs from crude porcine mucosal Hp preparations have been previously 
described4, and recent work has also highlighted the need for careful structural characterisation of such prepara-
tions to avoid potential production artefacts such as de-N-sulfated glucosamine32.
Here we undertook a systematic purification and analysis of the four major by-product fractions from the 
standard production process for Hp. We focussed on the Hp-like/HS GAGs contained in these fractions. To the 
best of our knowledge this is the first such analysis of these side fractions, which represent a valuable potential 
resource for this class of natural products. We established that, in terms of disaccharide composition, they are 
all clearly unique from each other and from Hp. The by-products differ most significantly in the proportions of 
disaccharides Δ-UA-GlcNAc(6S), Δ-UA(2S)-GlcNS and Δ-UA(2S)-GlcNS(6S). Average sulfation levels (~1.6 to 
2.1) were, as expected, lower than found in Hp (2.2). Although higher average sulfation broadly correlated with 
later stage of removal in the production process (in rank order D > B > A > C), Fraction C was an exception since 
it had the lowest sulfation. Thus the correlation was not absolute, suggesting that the purification processes may 
not fractionate solely on the basis of average charge, but also patterns of sulfation. It should be noted that Fraction 
C was obtained by a repeat of the purification step that was used to obtain B, and we would expect to see lower 
sulfated material that was not removed during the first round of this purification step.
Importantly, we did not observe detectable amounts of N-unsubstituted glucosamine (GlcN) in our prepa-
rations. Such moieties have recently been observed at high levels in some commercial preparations of porcine 
mucosal HS32, indicating that care is needed to subject final purified batches to detailed structural analysis such 
as those we have undertaken (especially rigorous NMR analysis), to ensure the integrity of the material in its 
natural form.
Figure 7. Proliferation of BaF3-1c cells was induced by Hp or by-products in response to FGF2. Cells were 
incubated in the presence of 0.1 nM FGF2 and a range of by-product samples or Hp control (1–100 µg/ml) 
for 72 hours. Proliferation was determined by MTT assay, reading the absorbance at 570 nm (n = triplicate 
of 3 biological repeats). The mean and standard error for each sample was calculated and multiple t-tests 
(p = 0.05) were carried out for all repeats, at all concentrations and samples were compared to Hp. P-values 
with a significant increase over Hp – 100 µg/ml A, 0.002, B, <0.0001, C, 0.002, D, <0.0001, 30 µg/ml A, 0.005, 
B, <0.0001, C, 0.0006, D, <0.0001, 10 µg/ml D, 0.01. P-values with a significant decrease below Hp – 3 µg/ml A, 
<0.0001, B, 0.002.
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In terms of chain size, all the by-products were larger than Hp, with average sizes ranging from ~19 kDa for 
the smallest (Fraction B) to ~34 kDa for the largest (Fraction C), compared to ~17 kDa for Hp. Regarding poly-
dispersity, we noted that the by-products were broadly similar (ranging from 1.7 to 2.2), all of them displaying 
much higher polydispersity than Hp (1.2; see Fig. 6). Our data suggest that the Hp production process progres-
sively reduces the polydispersity of the starting material to generate a more homogenous final Hp product. The 
polydispersity of the finished product is known to be manufacture dependent, with the average polydispersity of 
Hp on the market being 1.323, in good agreement with our current analysis. The reduction in polydispersity is also 
coupled with selection for increasing sulfation throughout the process (summarized in Fig. 6).
Importantly, we also demonstrated that side-fractions can be sub-fractionated by AEC (Fig. 2), indicating 
heterogeneity of these HS by-products as observed previously in HS samples purified from raw Hp4. The patterns 
of separation by AEC clearly demonstrated that each fraction is distinct from each other, as well as from Hp. 
Although Fractions B & C showed quite a similar range of fractions, they were present in different proportions 
(Fig. 2). Interestingly, the AEC data indicated that all materials contained some highly sulfated Hp-like material 
eluting at 1.8–2.0 M NaCl. Overall these heterogeneous patterns are significant as they demonstrate the presence 
of distinct sub-populations of HS. Furthermore, the AEC method we used is readily scalable and could be used 
for preparative production of these fractions, which could be exploited in future studies to generate a wider range 
of HS sub-preparations with variant sulfation levels and patterns. Such preparations could be exploited effectively 
in binding assays or bioassays to examine their differential protein interactions and bioactivities, and could also 
be exploited to develop more divergent oligosaccharide libraries via fractionation methods dependent on depo-
lymerisation, size and sulfation37.
As anticipated, the by-products we studied also displayed clear diversity in their functional properties. Firstly, 
the anticoagulant activity of the by-products is significantly reduced compared to Hp, similar to that observed for 
HS sub-fractions from crude Hp studied by Griffin et al.4. Furthermore, we found that all the by-products showed 
a large reduction in global and specific anticoagulant activity, increased activity correlating with the fractions 
removed later in the Hp production process (Table 3). Secondly, we found that all the by-products retain sub-
stantial biological activity comparable to that of Hp for promoting activation of FGF signalling. This was demon-
strated in an assay of cell signalling through FGF receptor 1c and FGF-2 (Fig. 7). Interestingly, side-products B 
and D showed a concentration dependent increase in cell proliferation, and both were significantly more active 
at low and high concentrations than Hp. We speculate that further sub-fractionation of the individual purified 
by-products, such as by AEC (Fig. 2), will be useful in future studies to separate different HS sub-species that will 
likely display variant activities in FGF signalling and other biological assays of HS-dependent mechanisms.
Analysis of the by-products further supports the view that Hp production succeeds in efficiently isolating the 
majority of Hp chains possessing high anticoagulant activity, and having high sulfation and low chain polydis-
persity. Clearly they represent a characteristic sub-set of Hp/HS fractions contained within raw Hp. Conversely, 
this results in the production of by-products with increased polydispersity, lower sulfation, and higher structural 
heterogeneity, which retain significant and divergent biological activities. It will be of significant interest in future 
studies to explore the 3-O-sulfate content of the by-products to investigate how this rare but important O-sulfate 
modification relates to anticoagulant and other bioactivities. Overall, these under-utilised waste products could 
therefore provide an economic and valuable source of useful bioactive natural products. These could be exploited 
to accelerate future structure-activity studies via oligosaccharide libraries33 and also to reveal new biomedical 
applications of these natural products as novel biomaterials38 or therapeutics.
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